Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nadolol in thyrotoxicosis.

N R Peden, T E Isles, I H Stevenson

    British Journal of Clinical Pharmacology
    |June 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Nadolol effectively treats thyrotoxicosis by reducing thyroid hormone levels and improving clinical symptoms. This non-selective beta-blocker demonstrates sustained beta-adrenoceptor blockade, though plasma concentrations vary individually.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Drugs in Hospital.

    Journal of the Royal College of Physicians of London·2019
    Same author

    The application of the fast, multi-hit, pixel imaging mass spectrometry sensor to spatial imaging mass spectrometry.

    The Review of scientific instruments·2012
    Same author

    The effect of fluphenazine on steady state plasma levels of nortriptyline.

    British journal of clinical pharmacology·2012
    Same author

    A trout fisherman with hypercalcaemia and skin lesions.

    Scottish medical journal·2011
    Same author

    Lateral sinus thrombosis due to acute mastoiditis; recovery with penicillin.

    Proceedings of the Royal Society of Medicine·2010
    Same author

    Accessory nasal sinusitis in childhood: With a record of bacteriological examinations.

    Archives of disease in childhood·2010
    Same journal

    UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

    British journal of clinical pharmacology·2026
    Same journal

    Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population-based cohort study.

    British journal of clinical pharmacology·2026
    Same journal

    Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus.

    British journal of clinical pharmacology·2026
    Same journal

    Impact of cumulative glucocorticoid exposure on vancomycin clearance in hospitalized children: A retrospective cohort study.

    British journal of clinical pharmacology·2026
    Same journal

    Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs.

    British journal of clinical pharmacology·2026
    Same journal

    Case-malformed signal detection and prioritisation using EUROmediCAT data for pharmacovigilance in pregnancy.

    British journal of clinical pharmacology·2026
    See all related articles

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Cardiology

    Background:

    • Thyrotoxicosis is a condition characterized by excessive thyroid hormone production.
    • Non-selective beta-adrenoceptor antagonists are used to manage hyperthyroid symptoms.

    Purpose of the Study:

    • To evaluate the efficacy and pharmacokinetic profile of nadolol in treating thyrotoxicosis.
    • To assess the duration of beta-adrenoceptor blockade achieved with daily dosing of nadolol.

    Main Methods:

    • Twenty outpatients with thyrotoxicosis were treated with nadolol as monotherapy for three weeks.
    • Clinical improvement was assessed using the thyrotoxicosis therapeutic index and heart rate response to exercise.
    • Plasma nadolol concentrations were measured to assess interindividual variability and correlation with clinical effects.

    Related Experiment Videos

    Main Results:

    • Nadolol treatment led to significant clinical improvement within the first week, sustained throughout the study.
    • Serum triiodothyronine (T3) levels decreased, while reverse T3 levels increased.
    • Once-daily 160 mg nadolol achieved 12-hour blockade in all patients and 24-hour blockade in most.
    • Steady-state plasma nadolol concentrations showed significant interindividual variability, influenced by age and renal function, and correlated with heart rate reduction.

    Conclusions:

    • Nadolol is an effective monotherapy for thyrotoxicosis, improving clinical outcomes and thyroid hormone profiles.
    • The drug provides sustained beta-adrenoceptor blockade, but dose-response relationships are influenced by individual factors like age and renal function.